TG Therapeutics, Inc., a commercial biopharmaceutical company, is dedicated to acquiring, developing, and commercializing innovative treatments for B-cell diseases, such as BRIUMVI, an anti-CD20 monoclonal antibody designed to treat adult patients with relapsing forms of multiple sclerosis (RMS). The company's portfolio includes Umbralisib, an oral inhibitor of PI3K-delta inhibitor for CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701, an orally available Bruton's tyrosine kinase (BTK) inhibitor showing selective activity to BTK in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. The company's research pipeline features other drug candidates. TG Therapeutics, Inc. holds license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd, and Rhizen Pharmaceuticals S A, for umbralisib development and commercialization. The firm has collaborations with Jiangsu Hengrui Medicine Co., Novimmune SA, Jubilant Biosys, and Checkpoint Therapeutics, Inc. with the last one being associated with the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs, especially hematological malignancies. TG Therapeutics, Inc. was established in 1993, and its headquarters is in Morrisville, North Carolina.